Trial Profile
Creatine Safety and Tolerability in Premanifest HD: PRECREST.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Creatine monohydrate (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms PRECREST
- 07 Feb 2014 Actual patients number changed from 67 to 64 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.